What is the share price of Gufic Biosciences Ltd (GUFICBIO) today?
The share price of GUFICBIO as on 5th December 2025 is ₹355.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Gufic Biosciences Ltd (GUFICBIO) share?
The past returns of Gufic Biosciences Ltd (GUFICBIO) share are- Past 1 week: -0.40%
- Past 1 month: 9.73%
- Past 3 months: -0.35%
- Past 6 months: -3.82%
- Past 1 year: -20.39%
- Past 3 years: 65.07%
- Past 5 years: 204.67%
What are the peers or stocks similar to Gufic Biosciences Ltd (GUFICBIO)?
The peers or stocks similar to Gufic Biosciences Ltd (GUFICBIO) include:What is the dividend yield % of Gufic Biosciences Ltd (GUFICBIO) share?
The current dividend yield of Gufic Biosciences Ltd (GUFICBIO) is 0.03.What is the market cap of Gufic Biosciences Ltd (GUFICBIO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gufic Biosciences Ltd (GUFICBIO) is ₹3564.04 Cr as of 5th December 2025.What is the 52 week high and low of Gufic Biosciences Ltd (GUFICBIO) share?
The 52-week high of Gufic Biosciences Ltd (GUFICBIO) is ₹498.25 and the 52-week low is ₹298.80.What is the PE and PB ratio of Gufic Biosciences Ltd (GUFICBIO) stock?
The P/E (price-to-earnings) ratio of Gufic Biosciences Ltd (GUFICBIO) is 51.16. The P/B (price-to-book) ratio is 5.93.Which sector does Gufic Biosciences Ltd (GUFICBIO) belong to?
Gufic Biosciences Ltd (GUFICBIO) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Gufic Biosciences Ltd (GUFICBIO) shares?
You can directly buy Gufic Biosciences Ltd (GUFICBIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Gufic Biosciences Ltd
GUFICBIO Share Price
355.400.77% (-2.75)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
GUFICBIO Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
GUFICBIO Performance & Key Metrics
GUFICBIO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 62.60 | 5.93 | 0.03% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.87 | 5.82 | 0.59% |
GUFICBIO Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
GUFICBIO Company Profile
Gufic Biosciences Limited manufactures pharmaceuticals, medicinal chemicals and botanical products. The Company's segments include Formulations, Bulk Drugs and Consumer.
SUNPHARMA
PE Ratio
39.63
39.63
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.04
67.04
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.77
18.77
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.21
29.21
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
GUFICBIO Sentiment Analysis
GUFICBIO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
GUFICBIO Stock Summary · November 2025
The company is strategically enhancing its operational capabilities, particularly at the Indore facility, which is on track for significant revenue contributions and improved margins by FY'27. With a focus on critical care and aesthetic segments, management anticipates robust growth driven by new product launches and international market expansion, despite challenges in regulatory compliance and pricing pressures. The positive sentiment surrounding the operational performance is bolstered by a commitment to reducing debt while optimizing resource allocation for future initiatives, including contract manufacturing and immuno-oncology projects. As the company navigates a competitive landscape, it remains dedicated to maintaining quality and reliability, positioning itself for sustainable growth in both domestic and international markets.
GUFICBIO Stock Growth Drivers
GUFICBIO Stock Growth Drivers
6Operational Performance and Financial Growth
Gufic Biosciences Limited has reported stable financial performance, with total revenue increasing from Rs. 227
Product Launches and Market Expansion
The company is actively expanding its product offerings, particularly in the toxin platform with Aesthaderm
GUFICBIO Stock Challenges
GUFICBIO Stock Challenges
4Increased Employee Expenses
The company has experienced a significant rise in employee expenses, primarily attributed to the operational
Rising Finance Costs
Finance costs have escalated due to changes in interest capitalization practices, with interest now being
GUFICBIO Forecast
GUFICBIO Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
GUFICBIO
GUFICBIO
Income
Balance Sheet
Cash Flow
Annual Normal View
GUFICBIO Income Statement
GUFICBIO Income Statement
Annual Normal View
| Financial Year | FY 2024 | FY 2025 | TTM | |||
|---|---|---|---|---|---|---|
| Total Revenue | 808.85 | 823.44 | 878.89 | |||
Raw Materials | 389.32 | 399.62 | 742.15 | |||
| Power & Fuel Cost | 17.61 | 18.46 | ||||
| Employee Cost | 109.67 | 127.19 | ||||
| Selling & Administrative Expenses | 105.28 | 122.48 | ||||
| Operating & Other expenses | 37.48 | 15.96 | ||||
EBITDA | 149.49 | 139.73 | 136.74 | |||
| Depreciation/Amortization | 17.02 | 21.06 | 27.95 | |||
| PBIT | 132.47 | 118.67 | 108.79 | |||
| Interest & Other Items | 16.79 | 24.52 | 32.12 | |||
| PBT | 115.68 | 94.15 | 76.67 | |||
| Taxes & Other Items | 29.54 | 24.49 | 19.74 | |||
| Net Income | 86.14 | 69.66 | 56.93 | |||
| EPS | 8.59 | 6.95 | 5.68 | |||
| DPS | 0.10 | 0.10 | 0.10 | |||
| Payout ratio | 0.01 | 0.01 | 0.02 |
GUFICBIO Company Updates
FY 2026FY 2026
Investor Presentation
Nov 14PDF
Aug 13PDF
GUFICBIO Stock Peers
GUFICBIO Past Performance & Peer Comparison
GUFICBIO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Gufic Biosciences Ltd | 51.16 | 5.93 | 0.03% |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
GUFICBIO Stock Price Comparison
Compare GUFICBIO with any stock or ETFCompare GUFICBIO with any stock or ETF
GUFICBIO
GUFICBIO Holdings
GUFICBIO Shareholdings
GUFICBIO Promoter Holdings Trend
GUFICBIO Promoter Holdings Trend
GUFICBIO Institutional Holdings Trend
GUFICBIO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
GUFICBIO Shareholding Pattern
GUFICBIO Shareholding Pattern
GUFICBIO Shareholding History
GUFICBIO Shareholding History
Foreign Institutions
Mutual Funds Invested in GUFICBIO
Mutual Funds Invested in GUFICBIO
No mutual funds holding trends are available
Top 5 Mutual Funds holding Gufic Biosciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3522% | Percentage of the fund’s portfolio invested in the stock 0.30% | Change in the portfolio weight of the stock over the last 3 months 0.30% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 173/199 (-18) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9130% | Percentage of the fund’s portfolio invested in the stock 0.80% | Change in the portfolio weight of the stock over the last 3 months -0.19% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 30/34 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4029% | Percentage of the fund’s portfolio invested in the stock 0.17% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 111/124 (-12) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing GUFICBIO stock
smallcases containing GUFICBIO stock
Looks like this stock is not in any smallcase yet.
GUFICBIO Events
GUFICBIO Events
GUFICBIO Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
GUFICBIO Dividend Trend
No dividend trend available
GUFICBIO Upcoming Dividends
GUFICBIO Upcoming Dividends
No upcoming dividends are available
GUFICBIO Past Dividends
GUFICBIO Past Dividends
Cash Dividend
Ex DateEx DateSep 22, 2025
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 22, 2025
Cash Dividend
Ex DateEx DateSep 17, 2024
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateSep 21, 2023
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 21, 2023
Cash Dividend
Ex DateEx DateAug 24, 2022
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Aug 24, 2022
Cash Dividend
Ex DateEx DateSep 9, 2021
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 9, 2021
GUFICBIO Stock News & Opinions
GUFICBIO Stock News & Opinions
Articles & Videos
Earnings
Gufic BioSciences consolidated net profit declines 22.74% in the September 2025 quarter
Net profit of Gufic BioSciences declined 22.74% to Rs 16.82 crore in the quarter ended September 2025 as against Rs 21.77 crore during the previous quarter ended September 2024. Sales rose 16.10% to Rs 237.05 crore in the quarter ended September 2025 as against Rs 204.18 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales237.05204.18 16 OPM %15.9618.91 - PBDT30.3833.55 -9 PBT22.6029.25 -23 NP16.8221.77 -23 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Gufic BioSciences to hold board meeting
Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Gufic BioSciences to conduct AGM
Gufic BioSciences announced that the Annual General Meeting(AGM) of the company will be held on 29 September 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Gufic BioSciences consolidated net profit declines 37.34% in the June 2025 quarter
Net profit of Gufic BioSciences declined 37.34% to Rs 13.07 crore in the quarter ended June 2025 as against Rs 20.86 crore during the previous quarter ended June 2024. Sales rose 10.31% to Rs 223.72 crore in the quarter ended June 2025 as against Rs 202.81 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales223.72202.81 10 OPM %14.8817.64 - PBDT24.9932.41 -23 PBT17.2728.10 -39 NP13.0720.86 -37 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Gufic BioSciences to convene board meeting
Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 13 August 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Gufic BioSciences appoints senior management personnel
Gufic BioSciences has appointed Rajesh Kaul as Senior President - Sparsh Cluster, Senior Management Personnel of the Company with effect from 04 July 2025. Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Gufic BioSciences consolidated net profit declines 61.50% in the March 2025 quarter
Net profit of Gufic BioSciences declined 61.50% to Rs 7.72 crore in the quarter ended March 2025 as against Rs 20.05 crore during the previous quarter ended March 2024. Sales rose 5.14% to Rs 205.02 crore in the quarter ended March 2025 as against Rs 194.99 crore during the previous quarter ended March 2024. For the full year,net profit declined 19.14% to Rs 69.65 crore in the year ended March 2025 as against Rs 86.14 crore during the previous year ended March 2024. Sales rose 1.63% to Rs 819.81 crore in the year ended March 2025 as against Rs 806.67 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales205.02194.99 5 819.81806.67 2 OPM %12.8717.55 -16.4318.08 - PBDT18.3731.46 -42 115.21132.69 -13 PBT10.5227.12 -61 94.14115.67 -19 NP7.7220.05 -61 69.6586.14 -19 Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Gufic BioSciences standalone net profit declines 60.25% in the March 2025 quarter
Net profit of Gufic BioSciences declined 60.25% to Rs 7.97 crore in the quarter ended March 2025 as against Rs 20.05 crore during the previous quarter ended March 2024. Sales rose 5.14% to Rs 205.02 crore in the quarter ended March 2025 as against Rs 194.99 crore during the previous quarter ended March 2024. For the full year,net profit declined 18.82% to Rs 69.93 crore in the year ended March 2025 as against Rs 86.14 crore during the previous year ended March 2024. Sales rose 1.63% to Rs 819.81 crore in the year ended March 2025 as against Rs 806.67 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales205.02194.99 5 819.81806.67 2 OPM %12.9917.55 -16.4618.08 - PBDT18.6131.46 -41 115.48132.70 -13 PBT10.7727.12 -60 94.42115.68 -18 NP7.9720.05 -60 69.9386.14 -19 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Board of Gufic BioSciences recommends final dividend
Gufic BioSciences announced that the Board of Directors of the Company at its meeting held on 30 May 2025, inter alia, have recommended the final dividend of Rs 0.1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Gufic BioSciences to announce Quarterly Result
Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant